{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:08:37Z","timestamp":1785355717490,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007278","name":"National University of Sciences and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03632-7","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:48:30Z","timestamp":1761047310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TAM family kinases are potential candidate targets for therapeutic intervention in chronic myeloid leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Maryam","family":"Yousaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Arif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilawar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"2 Suppl 3","key":"3632_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","volume":"41","author":"JL Spivak","year":"2004","unstructured":"Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41(2 Suppl 3):1\u20135. https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.011.","journal-title":"Semin Hematol"},{"issue":"4","key":"3632_CR2","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/s0950-3536(87)80031-8","volume":"1","author":"PC Shepherd","year":"1987","unstructured":"Shepherd PC, Ganesan TS, Galton DA. Haematological classification of the chronic myeloid leukaemias. Baillieres Clin Haematol. 1987;1(4):887\u2013906. https:\/\/doi.org\/10.1016\/s0950-3536(87)80031-8.","journal-title":"Baillieres Clin Haematol"},{"issue":"5","key":"3632_CR3","first-page":"1758","volume":"95","author":"P le Coutre","year":"2000","unstructured":"le Coutre P, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood J Am Soc Hematol. 2000;95(5):1758\u201366.","journal-title":"Blood J Am Soc Hematol"},{"issue":"5531","key":"3632_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876\u201380. https:\/\/doi.org\/10.1126\/science.1062538.","journal-title":"Science"},{"issue":"9","key":"3632_CR5","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.v99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, et al. High frequency of point mutations clustered within the adenosine triphosphate\u2013binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop Imatinib (STI571) resistance. Blood. J Am Soc Hematol. 2002;99(9):3472\u20135. https:\/\/doi.org\/10.1182\/blood.v99.9.3472.","journal-title":"J Am Soc Hematol"},{"issue":"9305","key":"3632_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N Von Bubnoff","year":"2002","unstructured":"Von Bubnoff N, et al. Bcr-abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359(9305):487\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(02)07679-1.","journal-title":"Lancet"},{"issue":"2","key":"3632_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1535-6108(02)00096-x","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor Imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2(2):117\u201325. https:\/\/doi.org\/10.1016\/s1535-6108(02)00096-x.","journal-title":"Cancer Cell"},{"issue":"16","key":"3632_CR8","doi-asserted-by":"publisher","first-page":"10700","DOI":"10.1073\/pnas.162140299","volume":"99","author":"S Roumiantsev","year":"2002","unstructured":"Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002;99(16):10700\u20135. https:\/\/doi.org\/10.1073\/pnas.162140299.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3632_CR9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, Ros\u00e9e L, M\u00fcller P, Lahaye MC, Hanfstein T, Schoch B, Cross C, Berger NC, Gschaidmeier U, Druker H, B. J., Hehlmann R. Molecular and chromosomal mechanisms of resistance to Imatinib (STI571) therapy. Leukemia. 2002;16(11):2190\u20136. https:\/\/doi.org\/10.1038\/sj.leu.2402741.","journal-title":"Leukemia"},{"issue":"11","key":"3632_CR10","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin AS, Ros\u00e9e L, Stoffregen P, Druker EP, Deininger MW. Several Bcr-Abl kinase domain mutants associated with Imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101(11):4611\u20134. https:\/\/doi.org\/10.1182\/blood-2002-12-3659.","journal-title":"Blood"},{"issue":"1","key":"3632_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-021-08450","volume":"21","author":"M Fatima","year":"2021","unstructured":"Fatima M, Kakar SJ, Adnan F, Khan K, Mian AA, Khan D. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia. BMC Cancer. 2021;21(1):713. https:\/\/doi.org\/10.1186\/s12885-021-08450-.","journal-title":"BMC Cancer"},{"issue":"10","key":"3632_CR12","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1535-7163.MCT-11-0116","volume":"10","author":"A Verma","year":"2011","unstructured":"Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther. 2011;10(10):1763\u201373. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0116.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3632_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","volume":"18","author":"KV Myers","year":"2019","unstructured":"Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer. 2019;18(1):94. https:\/\/doi.org\/10.1186\/s12943-019-1022-2.","journal-title":"Mol Cancer"},{"issue":"11","key":"3632_CR14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009076","volume":"5","author":"G Lemke","year":"2013","unstructured":"Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5(11):a009076. https:\/\/doi.org\/10.1101\/cshperspect.a009076.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"3632_CR15","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-16-1298","volume":"23","author":"Y Jin","year":"2017","unstructured":"Jin Y, Nie D, Li J, Du X, Lu Y, Li Y, et al. Gas6\/AXL signaling regulates self-renewal of chronic myelogenous leukemia stem cells by stabilizing \u03b2-catenin. Clin Cancer Res. 2017;23(11):2842\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1298.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3632_CR16","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.7150\/thno.91456","volume":"14","author":"N Vandewalle","year":"2024","unstructured":"Vandewalle N, Satilmis H, Verheye E, Fan R, Wang Y, De Groof TWM, et al. Axl-specific single domain antibodies show diagnostic potential and anti-tumor activity in acute myeloid leukemia. Theranostics. 2024;14(7):2656\u201374. https:\/\/doi.org\/10.7150\/thno.91456.","journal-title":"Theranostics"},{"issue":"5","key":"3632_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3892\/ol.2021.12658","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wei J, Liu J, Ma W, Duan Y, Liu D. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD+ acute myeloid leukemia cells. Oncol Lett. 2021;21(5):397. https:\/\/doi.org\/10.3892\/ol.2021.12658.","journal-title":"Oncol Lett"},{"issue":"14","key":"3632_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147715","volume":"23","author":"O Prado-Carrillo","year":"2022","unstructured":"Prado-Carrillo O, Arenas-Ram\u00edrez A, Llaguno-Munive M, Jurado R, P\u00e9rez-Rojas J, Cervera-Ceballos E, et al. Ketoconazole reverses Imatinib resistance in human chronic myelogenous leukemia K562 cells. Int J Mol Sci. 2022;23(14):7715. https:\/\/doi.org\/10.3390\/ijms23147715.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3632_CR19","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/leu.2009.69","volume":"23","author":"AA Mian","year":"2009","unstructured":"Mian AA, Sch\u00fcll M, Zhao Z, Oancea C, Hundertmark A, Beissert T, et al. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL. Leukemia. 2009;23(9):1614\u201321. https:\/\/doi.org\/10.1038\/leu.2009.69.","journal-title":"Leukemia"},{"issue":"9","key":"3632_CR20","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","volume":"71","author":"CA Eide","year":"2011","unstructured":"Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O\u2019Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011;71(9):3189\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3224.","journal-title":"Cancer Res"},{"key":"3632_CR21","doi-asserted-by":"crossref","unstructured":"Dymond JS. Explanatory chapter: quantitative PCR. In: Methods in enzymology. Elsevier; 2013. pp. 279\u201389.","DOI":"10.1016\/B978-0-12-418687-3.00023-9"},{"issue":"1","key":"3632_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.15171\/bi.2015.01","volume":"5","author":"Y Rahbar Saadat","year":"2015","unstructured":"Rahbar Saadat Y, Saeidi N, Vahed Z, Barzegari S, A., Barar J. An update to DNA ladder assay for apoptosis detection. BioImpacts: BI. 2015;5(1):25\u20138. https:\/\/doi.org\/10.15171\/bi.2015.01.","journal-title":"BioImpacts: BI"},{"issue":"1","key":"3632_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. Axl receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153. https:\/\/doi.org\/10.1186\/s12943-019-1090-3.","journal-title":"Mol Cancer"},{"key":"3632_CR24","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.12659\/msm.894554","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, Zhong H, Wang L, Dong Y, Jia A, Mo Q, et al. Mir-29 induces K562 cell apoptosis by down-regulating FoxM1. Med Sci Monit. 2015;21:3115\u201320. https:\/\/doi.org\/10.12659\/msm.894554.","journal-title":"Med Sci Monit"},{"issue":"17","key":"3632_CR25","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1093\/nar\/gkt584","volume":"41","author":"Y Chen","year":"2013","unstructured":"Chen Y, Zhang X, Dantas Machado AC, Ding Y, Chen Z, Qin PZ, et al. Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Res. 2013;41(17):8368\u201376. https:\/\/doi.org\/10.1093\/nar\/gkt584.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3632_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/path.838","volume":"194","author":"SC Wong","year":"2001","unstructured":"Wong SC, Chan JK, Lee KC, Hsiao WL. Differential expression of p16\/p21\/p27 and cyclin D1\/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol. 2001;194(1):35\u201342. https:\/\/doi.org\/10.1002\/path.838.","journal-title":"J Pathol"},{"issue":"4","key":"3632_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","volume":"116","author":"CM Gay","year":"2017","unstructured":"Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017;116(4):415\u201323. https:\/\/doi.org\/10.1038\/bjc.2016.428.","journal-title":"Br J Cancer"},{"issue":"1","key":"3632_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41467-018-03327-4","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018;9(1):1047. https:\/\/doi.org\/10.1038\/s41467-018-03327-4.","journal-title":"Nat Commun"},{"issue":"8","key":"3632_CR29","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/0008-5472.CAN-15-2119","volume":"76","author":"AL Hein","year":"2016","unstructured":"Hein AL, Seshacharyulu P, Rachagani S, Sheinin YM, Ouellette MM, Ponnusamy MP, et al. PR55\u03b1 subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling. Cancer Res. 2016;76(8):2243\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2119.","journal-title":"Cancer Res"},{"issue":"6","key":"3632_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41556-020-0507-y","volume":"22","author":"JM Perry","year":"2020","unstructured":"Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, Lu X, Nemechek J, Ruan L, Yu X, Dukes D, Moran A, Pace J, Schroeder K, Zhao M, Venkatraman A, Qian P, Li Z, Hembree M, Paulson A, Li L. Overcoming Wnt-\u03b2-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020;22(6):689\u2013700. https:\/\/doi.org\/10.1038\/s41556-020-0507-y.","journal-title":"Nat Cell Biol"},{"issue":"Pt 20","key":"3632_CR31","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1242\/jcs.00739","volume":"116","author":"S Haupt","year":"2003","unstructured":"Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci. 2003;116(Pt 20):4077\u201385. https:\/\/doi.org\/10.1242\/jcs.00739.","journal-title":"J Cell Sci"},{"key":"3632_CR32","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41467-021-22655-6","volume":"12","author":"H Wei","year":"2021","unstructured":"Wei H, Qu L, Dai S, et al. Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nat Commun. 2021;12:2280. https:\/\/doi.org\/10.1038\/s41467-021-22655-6.","journal-title":"Nat Commun"},{"key":"3632_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-610","volume":"10","author":"FH Gao","year":"2010","unstructured":"Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer. 2010;10:610. https:\/\/doi.org\/10.1186\/1471-2407-10-610.","journal-title":"BMC Cancer"},{"issue":"11","key":"3632_CR34","doi-asserted-by":"publisher","first-page":"874","DOI":"10.18632\/oncotarget.360","volume":"2","author":"M Dufies","year":"2011","unstructured":"Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S, Auberger P. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2011;2(11):874\u201385. https:\/\/doi.org\/10.18632\/oncotarget.360.","journal-title":"Oncotarget"},{"issue":"1","key":"3632_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.v99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319\u201325. https:\/\/doi.org\/10.1182\/blood.v99.1.319.","journal-title":"Blood"},{"issue":"11","key":"3632_CR36","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532\u20139. https:\/\/doi.org\/10.1182\/blood-2005-07-2947.","journal-title":"Blood"},{"issue":"23","key":"3632_CR37","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","volume":"68","author":"H Konig","year":"2008","unstructured":"Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008;68(23):9624\u201333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1131.","journal-title":"Cancer Res"},{"key":"3632_CR38","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","volume":"114","author":"RM Lemoli","year":"2009","unstructured":"Lemoli RM, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34\u2013 cell population with intrinsic resistance to Imatinib. Blood. 2009;114:5191\u2013200. https:\/\/doi.org\/10.1182\/blood-2008-08-176016.","journal-title":"Blood"},{"issue":"5","key":"3632_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4062\/biomolther.2020.051","volume":"28","author":"YS Ryu","year":"2020","unstructured":"Ryu YS, Shin S, An HG, Kwon TU, Baek HS, Kwon YJ, et al. Synergistic induction of apoptosis by the combination of an Axl inhibitor and auranofin in human breast cancer cells. Biomol Ther. 2020;28(5):473\u201381. https:\/\/doi.org\/10.4062\/biomolther.2020.051.","journal-title":"Biomol Ther"},{"key":"3632_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","volume":"10","author":"M Yadav","year":"2025","unstructured":"Yadav M, Sharma A, Patne K, et al. AXL signaling in cancer: from molecular insights to targeted therapies. Sig Transduct Target Ther. 2025;10:37. https:\/\/doi.org\/10.1038\/s41392-024-02121-7.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"3632_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-018-0584-6","volume":"11","author":"C Shi","year":"2018","unstructured":"Shi C, Li X, Wang X, Ding N, Ping L, Shi Y, et al. The proto-oncogene mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma. J Hematol Oncol. 2018;11(1):43. https:\/\/doi.org\/10.1186\/s13045-018-0584-6.","journal-title":"J Hematol Oncol"},{"key":"3632_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2021.101111","author":"NA Kafri","year":"2021","unstructured":"Kafri NA, Hafizi S. Identification of signalling pathways activated by Tyro3 that promote cell survival, proliferation and invasiveness in human cancer cells. Biochem Biophys Rep. 2021. https:\/\/doi.org\/10.1016\/j.bbrep.2021.101111.","journal-title":"Biochem Biophys Rep"},{"issue":"18","key":"3632_CR43","doi-asserted-by":"publisher","first-page":"9679","DOI":"10.1073\/pnas.94.18.9679","volume":"94","author":"JS Lanni","year":"1997","unstructured":"Lanni JS, Scott W, Lowe EJ, Licitra Jun O, Liu Jacks T. P53-independent apoptosis induced by Paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A. 1997;94(18):9679\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3632_CR44","doi-asserted-by":"publisher","unstructured":"Honeywell ME, Isidor MS, Harper NW, Fontana RE, Cruz-Gordillo P, Porto SA, Fraser CS, Sarosiek KA, Guertin DA, Spinelli JB, Lee MJ. p53 controls choice between apoptotic and non-apoptotic death following DNA damage. bioRxiv: the preprint server for biology, 2023.01.17.524444. 2023.\u00a0https:\/\/doi.org\/10.1101\/2023.01.17.524444","DOI":"10.1101\/2023.01.17.524444"},{"issue":"6697","key":"3632_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1126\/science.adh7950","volume":"384","author":"NJ Boon","year":"2024","unstructured":"Boon NJ, Oliveira RA, K\u00f6rner PR, Kochavi A, Mertens S, Malka Y, et al. DNA damage induces p53-independent apoptosis through ribosome stalling. Science. 2024;384(6697):785\u201392. https:\/\/doi.org\/10.1126\/science.adh7950.","journal-title":"Science"},{"key":"3632_CR46","doi-asserted-by":"publisher","first-page":"118992","DOI":"10.1016\/j.bbamcr.2021.118992","volume":"1868","author":"SM Sean","year":"2021","unstructured":"Sean SM, Andreeff M, DiNardo C, Khoury JD, Ruvolo PP. TAM kinases as regulators of cell death. Biochim et Biophys Acta (BBA) Mol Cell Res. 2021;1868:118992. https:\/\/doi.org\/10.1016\/j.bbamcr.2021.118992.","journal-title":"Biochim et Biophys Acta (BBA) Mol Cell Res."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03632-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:48:31Z","timestamp":1761047311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03632-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3632"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03632-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1944"}}